CSRxP proposals would undermine competitive market, harm patients and innovation

New CSRxP proposals would undermine the competitive market and harm patients and innovation.

Headshot of Robert Zirkelbach
Robert ZirkelbachApril 25, 2016

CSRxP proposals would undermine competitive market, harm patients and innovation

These so-called market-based proposals are nothing more than a litany of new government regulations and mandates that would undermine the competitive market and empower government bureaucrats and insurance companies to make one-size-fits-all treatment decisions for patients.

Rather than address health care costs holistically, these proposals only apply to the small share of health care spending that goes toward life-saving medicines while exempting the largest health care cost drivers, such as hospital charges, which include significant markups for prescription medicines.

Importantly, these proposals would not improve coverage and access for patients, despite recent data showing that out-of-pocket costs are soaring and that insurers are continuing to discriminate against patients with chronic health conditions, such as cancer, diabetes and rheumatoid arthritis.

Five facts about cost and coverage of prescription medicines:

Net_medicine_price_growth-1.jpg 

abc_graphic_on_KFF_study.png

ABC_ExhangeChart2016.png

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.